Drug Metabolism as a Community Effort

R. Hitchings; Libusha Kelly

doi:10.1016/j.cmet.2019.07.005

Drug Metabolism as a Community Effort

R. Hitchings
, Libusha Kelly

Systems & Computational Biology

Research output: Contribution to journal › Short survey › peer-review

8 Scopus citations

Abstract

Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.

Original language	English (US)
Pages (from-to)	235-237
Number of pages	3
Journal	Cell metabolism
Volume	30
Issue number	2
DOIs	https://doi.org/10.1016/j.cmet.2019.07.005
State	Published - Aug 6 2019

ASJC Scopus subject areas

Physiology
Molecular Biology
Cell Biology

Access to Document

10.1016/j.cmet.2019.07.005

Cite this

@article{8e259a9db36947fcae7b813dde6f7629,

title = "Drug Metabolism as a Community Effort",

abstract = "Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.",

author = "R. Hitchings and Libusha Kelly",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = aug,

day = "6",

doi = "10.1016/j.cmet.2019.07.005",

language = "English (US)",

volume = "30",

pages = "235--237",

journal = "Cell metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Drug Metabolism as a Community Effort

AU - Hitchings, R.

AU - Kelly, Libusha

PY - 2019/8/6

Y1 - 2019/8/6

N2 - Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.

AB - Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.

UR - https://www.scopus.com/pages/publications/85069941586

UR - https://www.scopus.com/pages/publications/85069941586#tab=citedBy

U2 - 10.1016/j.cmet.2019.07.005

DO - 10.1016/j.cmet.2019.07.005

M3 - Short survey

C2 - 31390549

AN - SCOPUS:85069941586

SN - 1550-4131

VL - 30

SP - 235

EP - 237

JO - Cell metabolism

JF - Cell metabolism

IS - 2

ER -

Drug Metabolism as a Community Effort

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this